Prevention of vascular risk factors could reduce incidence of Alzheimer's disease

NewsGuard 100/100 Score

Currently, no possibility exists to reliably quantify the risk of Alzheimer's disease (AD) onset in the general population and in subjects with mild cognitive impairment. Metabolic and genetic factors involved in increasing the probability of developing dementia have already been identified. Some vascular risk factors, as hypertension, dyslipidaemia, diabetes or smoking can cause a derangement in extra or intracranial vessels architecture, which can be responsible for an early aging of the brain. However, reliable tools for early identification of subjects at greater risk of evolution from mild cognitive impairment to AD are not available.

In a recent study, a research group from the Neurological Clinic of the University Hospital Ospedali Riuniti di Ancona and Marche Polytechnic University, Ancona, Italy, evaluated the reliability of the Framingham cardiovascular risk profile (FCRP) for the prediction of the evolution from mild cognitive impairment to AD. FCRP is a commonly adopted score used to calculate the risk of cardiovascular or cerebrovascular events along a 10-year period. Authors selected FCRP to evaluate if some common conditions, such as hypertension or diabetes, could be involved in increasing the risk of developing dementia. The results of this study are published in the Journal of Alzheimer's Disease.

The study, coordinated by Mauro Silvestrini and Leandro Provinciali with Giovanna Viticchi as principal investigator, demonstrated that in subjects affected by mild cognitive impairment, the presence of high FCRP scores is associated to an increased risk of developing AD. These results could have a relevant impact on the management of dementia because prevention of vascular risk factors and treatment of vascular damage can reduce the incidence of AD. Reducing and preventing the progression of vascular damage could represent a main therapeutic target for the prevention of cognitive deterioration.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study uncovers mutation impacting Alzheimer's progression